

REMARKS/ARGUMENTS

Claim 3, 7, 8 and 9 are amended herein.

Claim Rejections 35 U.S.C. § 112**Enablement**

Claim 9 is rejected as not enabled because it claims prevention of primary open angle glaucoma. Applicants have deleted prevention from this claim. Thus, this rejection is believed to be overcome.

Office takes the position that prevention of IOP does not extrapolate to all individuals. However, Applicants assert that any treatment of intraocular pressure that results in a prevention or a delay of the onset of glaucoma is within the scope of the present claims.

Indefiniteness

Claims 3, 7, and 8 were rejected as indefinite for being dependent upon cancelled claims 1 and 2. Claim 3 has been rewritten in dependent form, and claims 7 and 8 have been amended to depend from claim 3. Therefore, this rejection is believed to be overcome.

In light of the amendments made herein, Applicants believe that the claims are allowable. Therefore, Examiner is respectfully requested to pass them to issue.

Please charge Deposit Account 01-0885 for any fees related to this response.

Dated: April 10, 2008

Respectfully submitted,

/Brent A. Johnson/
Brent A. Johnson
Registration No. 51,851
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc. (T2-7H)
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714/246-4348
Facsimile: 714/246-4249